Oral AOD 9604: troches, capsules and bioavailability
Oral AOD 9604 — troches, capsules, lozenges, tablets, and nasal sprays — is attractive because needles are not. But the bioavailability question is central, and the honest answer explains why injectable protocols remain the standard.
- Oral AOD 9604 bioavailability is very low — the Phase IIb trial used oral doses of ~1 mg/kg/day to compensate.
- Troches and lozenges produce some sublingual absorption but systemic exposure is still much lower than injection.
- Oral formulations have a much milder side effect profile precisely because less peptide reaches the bloodstream.
- Nasal spray formulations have been attempted but lack robust pharmacokinetic data for AOD 9604 specifically.
- For equivalent effect, oral protocols require tens to hundreds of times more peptide than subcutaneous protocols.
Why oral AOD 9604 exists at all
From a commercial standpoint, an oral obesity drug is vastly more valuable than an injectable one — orders of magnitude more patients will take a pill than will inject themselves daily. Metabolic Pharmaceuticals knew this when they developed AOD 9604, which is why the pivotal Phase IIb trial used oral administration rather than subcutaneous injection. An approved oral AOD 9604 product would have been a landmark.
The problem is biology. AOD 9604 is a 15-amino-acid peptide, and peptides do not cross the gut wall efficiently. Gastric acid and proteolytic enzymes break them down before they can reach systemic circulation. Even with formulation strategies designed to protect the molecule, oral bioavailability for AOD 9604 is estimated to be in the low single-digit percentage range. That is why the trial used doses on the order of 1 mg/kg/day — to compensate for the fact that only a small fraction of each dose would reach the bloodstream.
Oral AOD 9604 formats
AOD 9604 has been formulated in several oral and mucosal formats, each with different absorption characteristics and practical tradeoffs.
Troches (lozenges)
A troche is a solid dose that dissolves slowly in the mouth, releasing peptide that can be absorbed through the oral mucosa rather than swallowed into the gastric environment. Sublingual absorption bypasses first-pass liver metabolism and avoids gastric acid degradation, so in theory a troche should produce higher bioavailability than a swallowed capsule. In practice, sublingual peptide absorption is still limited by molecule size and local enzyme activity. AOD 9604 troches tend to require 2–10 mg doses to achieve detectable systemic effects — roughly an order of magnitude more peptide than an equivalent subcutaneous dose.
Capsules and tablets
Oral AOD 9604 capsules and tablets are swallowed and processed through the digestive tract. These formulations face the full gut acid and enzyme barrier, and bioavailability is correspondingly the lowest of any route. They are rarely used in non-clinical protocols because the dose required to produce measurable effects is impractical. Their main appeal is convenience and the absence of the sublingual taste most users find unpleasant with troches.
Nasal spray
AOD 9604 nasal sprays exist but are poorly characterized. Intranasal delivery can produce rapid absorption for small peptides with appropriate formulation (insulin and oxytocin are examples), but AOD 9604's specific intranasal pharmacokinetics have not been published. Most "nasal spray AOD 9604" products on peptide markets are best treated as experimental rather than standard.
Subcutaneous injection (for comparison)
Subcutaneous injection remains the standard route used in research and in most non-clinical protocols because it is the only route with well-characterized pharmacokinetics. A 300 mcg subcutaneous dose produces substantially more systemic peptide exposure than a 5 mg oral dose — typically at a small fraction of the cost per effective milligram delivered.
Bioavailability comparison
| Route | Estimated bioavailability | Practical dose for equivalent effect |
|---|---|---|
| Subcutaneous | ~100% (reference) | 300 mcg |
| Sublingual troche | ~3–5% | 6–10 mg |
| Oral capsule/tablet | ~1–2% | 15–30 mg |
| Intranasal | Not well characterized | Variable |
These are approximate figures drawn from the general pharmacokinetics literature on small peptides and from the oral dose levels used in the Phase IIb clinical trial. They are not precise AOD 9604 bioavailability numbers — the published data on this specific molecule is limited.
Oral AOD 9604 side effects
The side effect profile of oral AOD 9604 is generally milder than injectable because the systemic exposure is lower. Most reported side effects from troches and lozenges are local — mild oral irritation, altered taste, occasional dry mouth — rather than systemic. The flip side is that the benefits are also smaller, and users who rely on oral formulations often see minimal results. For a full side effect breakdown across formats, see the AOD 9604 side effects page.
Practical summary
- If you want a format that actually matches the research dosing: subcutaneous injection.
- If you want a format with lower systemic exposure and milder effects: troche or lozenge, understanding that results will also be smaller.
- If you want an oral pill: possible, but practical doses are high and results are typically the weakest.
- If you want a nasal spray: data is sparse; treat as experimental.
For the underlying dosing math across all of these formats, see the AOD 9604 dosage page.
Frequently asked questions
Does oral AOD 9604 work?
It produces some effect but much weaker than subcutaneous injection because of poor oral bioavailability. The Phase IIb clinical trial used oral doses of approximately 1 mg/kg/day to compensate and still did not meet its primary endpoint.
Are AOD 9604 troches better than capsules?
Slightly, yes. Sublingual absorption through the oral mucosa bypasses gastric acid and first-pass liver metabolism, so troches tend to achieve somewhat higher bioavailability than swallowed capsules — though both are much lower than subcutaneous injection.
What's the AOD 9604 oral dose?
In clinical research, oral doses of approximately 1 mg/kg body weight per day were used — roughly 54 mg/day for a 60 kg adult. That is 180 times the typical subcutaneous dose, reflecting how much more peptide is needed to compensate for oral bioavailability.
Do AOD 9604 nasal sprays work?
Pharmacokinetic data on intranasal AOD 9604 is limited. Intranasal delivery can work well for some small peptides, but AOD 9604's specific absorption profile through the nasal mucosa has not been robustly characterized.
Why are oral AOD 9604 side effects milder?
Because less peptide reaches systemic circulation. Troches and lozenges tend to produce only local oral effects — mild irritation, altered taste — rather than the systemic profile seen with injectable protocols.